Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
ConditionUreteral Stent-Related Symptom
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBir Hospital
About this trial
A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.
Eligibility criteria
Qualifiers
None
Disqualifiers
Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics
Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy
Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases
Preoperative febrile Urinary Tract Infection (UTI)
Trial design
Treatments tested in this trial
- Tamsulosin Hydrochloride 0.4 mg
- Solifenacin Succinate 5 mg
- Mirabegron 25 mg
Treatment groups
189 Participants
are divided into 3 treatment groupsSponsors and collaborators
Bir Hospital
Lead sponsor
Nepal Health Research Council
Collaborator
Source ClinicalTrials.gov